Vaccine Uptake Per 1000 People By Dhb Of Residence
There will be no production plans from 30 August to 3 October. The increased vaccination demand caused by the August 2021 outbreak means the plans collected earlier do not provide a good comparator. As a result the table comparing cumulative performance to plan has been removed. Historic performance against plan is still available in the Excel spreadsheet.
What Do We Know About The Astrazeneca Adenovirus Covid
An analysis of Phase 3 clinical trial data suggests that the COVID-19 vaccine developed by AstraZeneca and the University of Oxford is effective and safe. AstraZeneca presented interim results in a press release on March 22, 2021. Within a day, however, the National Institutes of Allergy and Infectious Diseases released a statement expressing concern that AstraZeneca’s analysis may contain outdated information and may provide “an incomplete view of the efficacy data.” On March 25th, AstraZeneca released a new analysis, also in a press release, that included more recent trial data. The FDA will have the opportunity to carefully examine and conduct its own analysis of all of the trial data when AstraZeneca applies for emergency use authorization , which is expected to happen in the coming weeks.
According to AstraZeneca’s most recent analysis, vaccine recipients were 76% less likely to develop symptomatic COVID infection than those who received a placebo. The vaccine was also 100% effective for protecting against severe COVID and hospitalization there were eight cases of severe COVID in the placebo group, compared to none in the vaccine group.
The analysis looked at results from a trial of about 32,000 participants from the US, France, Chile, and Peru. Two-thirds of the study participants were randomly selected to received two doses of the vaccine, spaced four weeks apart. The remaining one-third of participants got a saltwater placebo.
Map: How Many People Have Been Vaccinated In Each State
States prioritized at-risk populations to be vaccinated first, including medical staff, people in nursing homes or other long-term care facilities, essential workers, the elderly and people with medical conditions that put them at greater risk of becoming seriously ill with COVID-19.
Any person age 12 and older in the U.S. is now eligible to receive a COVID-19 vaccine.
Recommended Reading: Cvs Covid Testing Result Time
Chart: How Many Shots From Each Vaccine Manufacturer Have Been Administered
The Pfizer-BioNTech and Moderna vaccines require two doses, and the Johnson & Johnson vaccine requires only one for the recipient to be fully vaccinated. For the Pfizer-BioNTech and Moderna vaccines, a second shot should be administered about three or four weeks after the first, depending on which of the vaccines was given.
Read more:Comparing the COVID-19 vaccines
Are There Any Groups Of People Who Should Not Get The Mrna Covid
There are only a few groups of people who should not get the mRNA vaccine. They include people who
- are allergic to any components of the mRNA vaccine, which include polyethylene glycol and polysorbate
- had an allergic reaction within the first 30 minutes after receiving the first dose of an mRNA COVID-19 vaccine.
If you have a history of allergic reactions to other vaccines or to injectable medications, ask your doctor if it is safe for you to get one of the currently available mRNA vaccines.
Finally, it is possible that convalescent plasma or monoclonal antibodies, both of which are used to treat COVID-19, could reduce the effectiveness of the vaccine. If you have received either of these treatments, wait 90 days before getting your vaccine.
Read Also: How Long Cvs Covid Test Results
What Do We Know About The Novavax Covid
The Novavax COVID-19 vaccine appears to be effective and safe, according to an analysis of phase 3 trial results released by the company in a press release. The trial found the vaccine to be 90% effective overall, and 100% effective against moderate and severe disease. The vaccine requires two doses, given three weeks apart, and may be stored using standard refrigeration.
The PREVENT-19 trial enrolled 29,960 participants, ages 18 years and older, across the US and Mexico. Two-thirds of the participants received the Novavax vaccine and one-third received a placebo. The trial was randomized, and observer-blinded, meaning the study participants and those evaluating the study endpoints did not know which participants received the vaccine.
Between January 25 and April 30, 2021, there were 77 confirmed cases of COVID-19 among the study participants. Of these, 63 occurred in the placebo group and 14 occurred in the vaccine group. All of the cases that occurred in the vaccine group were mild. Of those that occurred in the placebo group, 10 were moderate and four were severe. This translated to 100% efficacy against moderate and severe disease. The vaccine was 91% effective in people at high risk, which the study defined as people 65 years or older, with a medical condition that increased risk of severe COVID illness, or whose jobs increased their risk of exposure to COVID-19.
Side effects from the vaccine included arm pain at the injection site, fatigue, headache, and muscle pain.
Reuse Our Work Freely
All visualizations, data, and code produced by Our World in Data are completely open access under the Creative Commons BY license. You have the permission to use, distribute, and reproduce these in any medium, provided the source and authors are credited.
The data produced by third parties and made available by Our World in Data is subject to the license terms from the original third-party authors. We will always indicate the original source of the data in our documentation, so you should always check the license of any such third-party data before use and redistribution.
All of our charts can be embedded in any site.
Recommended Reading: How Long Does It Take To Get Covid 19 Test Results From Cvs
How Many Cases Vaccinations And Deaths In My Area
Enter a full UK postcode or council name to find out
From late September, healthy children aged 12 to 15 will also be offered one dose of a vaccine.
The vaccine rollout, launched in winter 2020, began with those considered most vulnerable and later moved down the age groups.
The government has now launched a booster campaign, with frontline health and social care workers the first to receive a third dose.
Boosters will also be offered to the over-50s and younger adults with certain health conditions.
So far, the UK has approved four vaccines for use: Pfizer-BioNTech, Oxford-AstraZeneca, Moderna and Janssen three of which require two doses for maximum protection.
Al those aged under 40 are being offered an alternative to the Oxford-AstraZeneca vaccine due to evidence linking it to rare blood clots.
The vaccine currently being used for under-18s in the UK is Pfizer-BioNTech, but the Moderna vaccine has also been authorised for use in children.
Those eligible for boosters will receive one dose of Pfizer or half a dose of Moderna.
There is no vaccine currently approved for use in the under-12s.
How Have The Vaccines Performed The Real World Are They Working As Well As They Did In Clinical Trials
In a study published online in MMWR, the CDC reported that people who had received both doses of either mRNA vaccine were 90% less likely to get infected with COVID-19 than people who were not vaccinated. In clinical trials, the vaccines were 95% and 94.1% effective.
The MMWR study enrolled 3950 adults who were at high risk of exposure to the virus due to their jobs and followed them for 13 weeks, beginning in mid-December 2020. About 63% of the study participants received both doses of vaccine during the study period and an additional 12% received one dose during the study. Each week, the study participants sent a nasal swab for PCR testing, and they reported any symptoms, allowing the researchers to identify both symptomatic and asymptomatic infections.
A total of 180 COVID-19 infections occurred during the study period. Of these, 161 infections were in people who were unvaccinated, compared to three infections in people who were fully vaccinated. Sixteen people who had received only their first vaccine dose at least two weeks earlier were infected. While this translates to one dose preventing 80% of infections, the study did not measure how well the vaccine protects people who do not get the second dose.
The researchers did not comment on variants, and the study was not designed to measure the effectiveness of the vaccines against them. However, its worth noting that several viral variants were circulating during the study period.
Also Check: How Long Covid Live On Fabric
Map: How Many People Are Vaccinated In Each County
County-level data is most accurate in states that report county of residence to the CDC for a high percentage of people vaccinated. In states that report the county of residence at a lower rate, the vaccination rate for counties may appear to be lower than it actually is.
For this reason, data is not shown for states that included a county of residence for less than 80% of people vaccinated there. Some states, such as Texas and Hawaii, do not report county-level information to the CDC.
What Share Of The Population Has Been Partly Or Fully Vaccinated Against Covid
The following charts show the breakdown of vaccinations by those that have been partly or fully vaccinated. A person is considered partly vaccinated if they have received only one dose of a 2-dose vaccine protocol. A person is considered fully vaccinated if they have received a single-dose vaccine or both doses of a two-dose vaccine.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
Recommended Reading: Cvs Covid Testing How Long For Results
What You Need To Know
- COVID-19 vaccines are safe and effective.
- Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring in U.S. history.
- CDC recommends everyone 12 years and older get vaccinated as soon as possible to help protect against COVID-19 and the related, potentially severe complications that can occur.
- CDC, the U.S. Food and Drug Administration , and other federal agencies are monitoring the safety of COVID-19 vaccines.
- Adverse events described on this page have been reported to the Vaccine Adverse Event Reporting System external icon.
- VAERS accepts reports of any adverse event following any vaccination.
- Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem.
Serious adverse events after COVID-19 vaccination are rare but may occur.
For public awareness and in the interest of transparency, CDC is providing timely updates on the following serious adverse events of interest:
Fact Check: Have 966 People Died After Receiving The Covid Vaccine
The U.S. COVID vaccine rollout has seen over 90 million people receive at least one dose, according to Centers for Disease Control and Prevention data as of March 7.
Scientists told Newsweek on February 24 that serious side-effects from the vaccine were rare at a time when 65 million doses had been given. Some examples of common reported side-effects include pain at the site of injection and tiredness.
There also have been reports of people dying after receiving a vaccine, based on data from the CDC’s Vaccine Adverse Event Reporting System reporting database. VAERS is a U.S.-based early warning system for vaccine side-effects.
Healthcare professionals are required to report certain adverse events that occur after vaccines to the system, but it is not designed to give information on what caused the events, such as deaths.
Recommended Reading: How Long Do Cvs Covid Tests Take
What Do We Know About The Moderna Covid
On December 18, 2020, the FDA granted emergency use authorization to an mRNA COVID-19 vaccine developed by Moderna in collaboration with scientists from the NIH. The vaccine is approved for use in people 18 years and older. This is the second COVID-19 vaccine authorized for use in the US.
The FDA granted EUA based on their own analysis of efficacy and safety data, as well as on the recommendation made by the Vaccines and Related Biological Products Advisory Committee . VRBPAC is a group of outside experts in infectious disease, vaccinology, microbiology, immunology, and other related fields.
In briefing documents submitted to the FDA, the Moderna vaccine showed an overall efficacy of 94.1% in preventing COVID-19. This study enrolled 30,400 adults half received the vaccine, half received a saltwater placebo shot. There were 196 infections among the study participants. Of these, 185 were in the placebo group and 11 were in the vaccine group. All 30 cases of severe COVID occurred in the placebo group, strongly suggesting indicating that the vaccine reduces risk of severe illness.
The vaccine was similarly effective in people older and younger than 65, in men and women, in people with and without medical conditions that put them at high risk for severe illness, and in different racial and ethnic groups.
The most common vaccine side effects were pain at the injection site, fatigue, headache, muscle pain, joint pain, and chills.
What Do We Know About The Pfizer/biontech Covid
In August 2021, the FDA granted full approval to the Pfizer/BioNTech COVID-19 mRNA vaccine for use in people ages 16 years and older. The transition from emergency use authorization status to full licensure was based on additional data and longer follow-up showing that the vaccine met certain safety, effectiveness, and manufacturing quality standards.
Previous milestones for the Pfizer/BioNTech COVID-19 vaccine include the following:
- In December 2020, the FDA granted EUA to the Pfizer/BioNTech vaccine in people ages 16 years and older. It was the first COVID-19 vaccine to receive EUA.
- In May 2021, the FDA expanded its EUA for the Pfizer/BioNTech vaccine to include adolescents 12 to 15 years old.
- In August 2021, the FDA authorized a third dose of mRNA vaccine for certain people with a weakened immune response.
The FDA granted its original EUA based on their own analysis of efficacy and safety data as well as on the recommendation made by the Vaccines and Related Biological Products Advisory Committee on December 10th. VRBPAC is a group of outside experts in infectious disease, vaccinology, microbiology, immunology, and other related fields.
None of the study participants experienced serious side effects. However, most did have pain at the injection site. Also, about half of those receiving the vaccine reported mild to moderate fatigue or headache or both. Chills and fever were also fairly common. Symptoms almost always resolved within 24 to 48 hours.
Also Check: How Long Cvs Covid Test Results
What Are Mrna Vaccines And How Do They Work To Help Prevent Covid
mRNA, or messenger RNA, is genetic material that contains instructions for making proteins. mRNA vaccines for COVID-19 contain synthetic mRNA. Inside the body, the mRNA enters human cells and instructs them to produce the “spike” protein found on the surface of SARS-CoV-2, the virus that causes COVID-19. The body recognizes the spike protein as an invader, and starts producing antibodies against it. Soon after, the cell breaks down the mRNA into harmless pieces If the antibodies later encounter the actual virus, they are ready to recognize and destroy it before it causes illness.
Two mRNA vaccines, one created by Pfizer and BioNTech and another developed by Moderna, were granted emergency use authorization by the FDA in December 2020. In August 2021, the FDA granted full approval to the Pfizer/BioNTech COVID-19 mRNA vaccine for use in people ages 16 years and older. The transition from EUA status to full licensure was based on additional data and longer follow-up showing that the vaccine met certain safety, effectiveness, and manufacturing quality standards.
What Are Breakthrough Infections And Why Do They Happen
A breakthrough infection is one that occurs after full vaccination.
In an article published in MMWR, the CDC reported 10,262 breakthrough infections through the end of April 2021. By that point, more than 100 million Americans had received the COVID-19 vaccine.
The vast majority of breakthrough infections were asymptomatic, mild, or moderate. About 1,000 people with breakthrough infections were hospitalized, and 160 died, though the hospitalizations and deaths were not always related to COVID-19.
These numbers tell us that the vaccines are doing a good job preventing infection and severe illness. None of the vaccines were 100% effective in clinical trials, so a small number of breakthrough infections was expected.
You May Like: Cvs Corona Test Results
Africa Will Fall Short Of Its Vaccination Targets Even If The Vaccine Rollout Accelerates Significantly
Even Africas modest vaccination goals this year appear out of reach.
The African Union, aware of the challenge of obtaining enough vaccines, hoped to immunize 20 percent of its population by years end. The International Monetary Fund proposed a more ambitious goal: 40 percent immunization this year, and 60 percent by mid-next year. But reaching either of those goals would require a huge change in current vaccination rates.
Why Did The Fda And Cdc Recommend Temporarily Pausing Use Of The Johnson & Johnson Covid
On April 13, 2021, the FDA and CDC jointly recommended pausing use of the Johnson & Johnson COVID-19 vaccine until the agencies could review the cases of a rare but serious type of blood clot that were reported in six women who received the Johnson & Johnson vaccine. On April 23, the FDA and CDC recommended lifting the pause, and allowing use of the vaccine to resume. They made this decision after their medical and scientific teams examined the data and determined that the vaccines known and potential benefits outweigh its known and potential risks.
The Johnson & Johnson vaccine is once again available for use in the US, for anyone ages 18 and older. However, the vaccines label and factsheet will now warn of the rare risk of developing blood clots involving blood vessels in the brain, abdomen, and legs, along with low levels of blood platelets. The label and factsheet also list symptoms of TTS and urge anyone who experiences them after receiving the Johnson & Johnson vaccine to seek immediate medical attention.
Since the FDA granted emergency use authorization for the Johnson & Johnson vaccine in late February, more than 8 million doses of the one-dose vaccine have been given. A total of 15 cases of TTS were reported through April 23rd all occurred in women between the ages of 18 and 59, between six and 15 days after vaccination.
- severe headache
- tiny red spots on the skin
- new or easy bruising or bleeding.
Read Also: How Long Cvs Covid Test Results